Soluble CD33 for treating myelodysplastic syndromes (MDS)

Patent metadata

Field	Value
Publication number	US-10344072-B2
Application number	US-201414902719-A
Country	US
Kind code	B2
Filing date	Jul 3, 2014
Priority date	Jul 5, 2013
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

First claim

What is claimed is:

1. A method for treating myelodysplastic syndrome (MDS) in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a soluble CD33 fusion protein that binds and sequesters S100A9, wherein the fusion protein comprises an extracellular domain of human CD33 and an immunoglobulin Fc region, wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:1, or an amino acid sequence having at least 95% identity to SEQ ID NO:1.

2. The method of claim 1 , wherein the fusion protein comprises a formula selected from the group consisting of:
eCD33-Fc,
eCD33-eTLR4-Fc,
eCD33-eRAGE-Fc,
eCD33-eTLR4-eRAGE-Fc,
eCD33-eRAGE-eTLR4-Fc,
eTLR4-eCD33-eRAGE-Fc,
eRAGE-eCD33-eTLR4-Fc,
eTLR4-eRAGE-eCD33-Fc, and
eRAGE-eTLR4-eCD33-Fc,
wherein “eCD33” comprises the extracellular domain of human CD33,
wherein “eTLR4” comprises an extracellular domain of TLR4,
wherein “eRAGE” comprises an extracellular domain of RAGE,
wherein “Fc” comprises the immunoglobulin Fc region, and
wherein “-” consists of a peptide linker or a peptide bond,
wherein the extracellular domain of TLR4 comprises the amino acid sequence SEQ ID NO:5, or an amino acid sequence having at least 90% identity to SEQ ID NO:5, and
wherein the extracellular domain of RAGE comprises the amino acid sequence SEQ ID NO:6, or an amino acid sequence having at least 90% identity to SEQ ID NO:6.

3. The method of claim 1 , wherein the fusion protein further comprises a biotin acceptor peptide that can be biotinylated with biotin ligase (BirA) in the presence of biotin and ATP.

4. The method of claim 3 , wherein the fusion protein comprises a formula selected from the group consisting of:
eCD33-Fc-Avi,
eCD33-eTLR4-Fc-Avi,
eCD33-eRAGE-Fc-Avi,
eCD33-eTLR4-eRAGE-Fc-Avi,
eCD33-eRAGE-eTLR4-Fc-Avi,
eTLR4-eCD33-eRAGE-Fc-Avi,
eRAGE-eCD33-eTLR4-Fc-Avi,
eTLR4-eRAGE-eCD33-Fc-Avi, and
eRAGE-eTLR4-eCD33-Fc-Avi,
wherein “eCD33” comprises the extracellular domain of human CD33,
wherein “eTLR4” comprises an extracellular domain of TLR4,
wherein “eRAGE” comprises an extracellular domain of RAGE,
wherein “Fc” comprises the immunoglobulin Fc region,
wherein “Avi” comprises the biotin acceptor peptide that can be biotinylated with biotin ligase (BirA) in the presence of biotin and ATP, and
wherein “-” consists of a peptide linker or a peptide bond,
wherein the extracellular domain of TLR4 comprises the amino acid sequence SEQ ID NO:5, or an amino acid sequence having at least 90% identity to SEQ ID NO:5, and
wherein the extracellular domain of RAGE comprises the amino acid sequence SEQ ID NO:6, or an amino acid sequence having at least 90% identity to SEQ ID NO:6.

5. The method of claim 3 , wherein the biotin acceptor peptide comprises the amino acid sequence SEQ ID NO:7, or an amino acid sequence having at least 90% identity to SEQ ID NO:7.

6. The method of claim 1 , wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:1, or an amino acid sequence having at least 97% identity to SEQ ID NO:1.

7. The method of claim 6 , wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:2.

8. The method of claim 1 , wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:3.

9. The method of claim 1 , wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:4.

10. The method of claim 1 , wherein the composition comprises a multimeric complex comprising two or more soluble CD33 fusion proteins conjugated to a core molecule or particle.

11. The method of claim 10 , wherein the core molecule is streptavidin, and wherein the two or more soluble CD33 fusion proteins are biotinylated.

12. The method of claim 10 , wherein the core molecule is a liposome comprising antibodies that specifically bind the two or more soluble CD33 fusion proteins.

13. The method of claim 10 , wherein the core molecule is a liposome comprising antibodies that specifically bind a biotin acceptor peptide.

14. The method of claim 10 , comprising from 2 to 5 soluble CD33 fusion proteins conjugated to the core molecule or particle.

15. The method of claim 1 , wherein the extracellular domain of human CD33 comprises the amino acid sequence SEQ ID NO:1.

Assignees

• H Lee Moffitt Cancer Ct & Res

Inventors

• List Alan F
• Wei Sheng

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title